• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Neuraxis Inc.

    10/8/25 4:11:47 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NRXS alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on October 8, 2025.

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

     

    NEURAXIS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   45-5079684
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    11611 N. Meridian Street, Suite 330

    Carmel, IN 46032

    Telephone: (812) 689-0791

    (Address, including zip code and telephone number, including area code, of registrant’s principal executive offices)

     

    NEURAXIS, INC. 2025 EMPLOYEE STOCK PURCHASE PLAN

    NEURAXIS, INC. 2022 OMNIBUS SECURITIES AND INCENTIVE PLAN

    (Full title of the plan)

     

    Brian Carrico

    Chief Executive Officer

    Neuraxis, Inc.

    11611 N. Meridian Street, Suite 330

    Carmel, IN 46032

    Telephone: (812) 689-0791

    (Name, address and telephone number, including area code, of agent for service)

     

    Copies to:

    Joseph M. Lucosky, Esq.

    Steven A. Lipstein, Esq.

    Lucosky Brookman LLP

    101 Wood Avenue South, 5th Floor

    Woodbridge, NJ 08830

    (732) 395-4496

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement on Form S-8 (the “Registration Statement”) in accordance with the provisions of Rule 428 under the Securities Act of 1933 (the “Securities Act”) and the introductory note to Part I of Form S-8.

     

    The document(s) containing the information specified in Part I will be sent or given to employees as specified by Rule 428(b)(1) of the Securities Act. Such documents are not required to be, and are not, filed with the Securities and Exchange Commission (the “Commission”) either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed by the Registrant with the Commission are incorporated as of their respective dates in this Registration Statement by reference:

     

    ● Our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 20, 2025;

     

    ● Our Quarterly Report on Form 10-Q for the period ended March 31, 2025, filed with the SEC on May 12, 2025, and Quarterly Report on Form 10-Q for the period ended June 30, 2025, filed with the SEC on August 12, 2025;

     

    ● Our Current Reports on Form 8-K filed with the SEC on May 21, 2025, May 22, 2025, July 3, 2025 and September 2, 2025 (in each case, except for information contained therein which is furnished rather than filed); and

     

    ● The description of our Common Stock contained in our registration statement on Form 8-A12B filed with the SEC on August 8, 2023.

     

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act (excluding any portions thereof furnished by the Registrant, including information furnished under Item 2.02 and Item 7.01 and any exhibits relating to Item 2.02 or Item 7.01 furnished under Item 9.01 of Form 8-K and any certification required by 18 U.S.C. § 1350), subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    Section 145(a) of the Delaware General Corporate Law (the “DGCL”) provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

     

     

     

     

    Section 145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.

     

    Section 145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under Section 145 of the DGCL.

     

    Additionally, our bylaws eliminates our directors’ liability to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability:

     

    ● for any transaction from which the director derives an improper personal benefit;

     

    ● for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

    ● for any unlawful payment of dividends or redemption of shares; or

     

    ● for any breach of a director’s duty of loyalty to the corporation or its stockholders.

     

    If the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the Company’s directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

     

    We are also expressly authorized to carry directors’ and officers’ insurance to protect our directors, officers, employees and agents against liabilities for actions taken in their capacities as directors and officers.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits

     

    The exhibits listed on the exhibit index at the end of this Registration Statement are included in this Registration Statement.

     

    EXHIBITS

     

    Exhibit No.   Description
    5.1*   Opinion of Lucosky Brookman LLP, counsel to the Registrant
         
    23.1*   Consent of Rosenberg Rich Baker Berman, P.A., Independent Registered Public Accounting Firm for the Registrant
         
    23.3*   Consent of Lucosky Brookman LLP (included in Exhibit 5.1)
         
    24.1*   Power of Attorney (included as part of the signature pages to this Registration Statement)
         
    99.1   Neuraxis, Inc. 2025 Employee Stock Purchase Plan (incorporated by reference to exhibit 10.2 to Current Report on Form 8-K, filed on July 3, 2025)
         
    99.2   Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.21 to Registration Statement on Form S-1, filed on January 10, 2023)
         
    107*   Filing Fee Table

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    The Registrant. Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Carmel, IN, State of Indiana on the 8th day of October, 2025.

     

      NEURAXIS, INC.
         
      By: /s/ Brian Carrico
      Name: Brian Carrico
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints Brian Carrico, his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to sign any registration statement for the same offering covered by the Registration Statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agent, or his, her or their substitute or substitutes, may lawfully do or cause to be done or by virtue hereof.

     

    Signature   Title   Date
             
    /s/ Brian Carrico   Chief Executive Officer and Director   October 8, 2025
    Brian Carrico   (principal executive officer)    
             
    /s/ Timothy Henrichs   Chief Financing Officer   October 8, 2025
    Timothy Henrichs   (principal financial officer and principal accounting officer)    
             
    /s/ Christopher Robin Brown   Director   October 8, 2025
    Christopher Robin Brown        
             
    /s/ Bradley Mitch Watkins   Director   October 8, 2025
    Bradley Mitch Watkins        
             
    /s/ Beth Keyser   Director   October 8, 2025
    Beth Keyser        
             
    /s/ Kristin Ferge   Director   October 8, 2025
    Kristin Ferge        
             

     

     

     

    Get the next $NRXS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NRXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Carrico Brian Allen

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:56 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:53 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferge Kristin A was granted 13,157 shares, increasing direct ownership by 1,112% to 14,340 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    9/10/25 6:32:54 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

    Achieves significant expansion of NeurAxis' total addressable marketClearance now includes patients aged "8 years and older"Expanded age indication will utilize the upcoming January 1st, 2026, Category I CPT code to report PENFS procedures CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it has received FDA 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (PENFS) technology for the treatment of functional abdominal pain (FAP) associated

    10/24/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

    CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 11:00 a.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at

    9/18/25 8:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Hannasch Brian bought $800,001 worth of shares (355,556 units at $2.25), increasing direct ownership by 46% to 1,131,522 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    7/3/25 11:24:27 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Hannasch Brian bought $31,251 worth of shares (18,065 units at $1.73), increasing direct ownership by 2% to 775,966 units (SEC Form 4)

    4 - Neuraxis, INC (0001933567) (Issuer)

    4/23/25 4:38:50 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    SEC Filings

    View All

    Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/24/25 8:22:36 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:27:48 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Neuraxis Inc.

    424B5 - Neuraxis, INC (0001933567) (Filer)

    10/23/25 5:26:10 PM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Leadership Updates

    Live Leadership Updates

    View All

    NeurAxis Appoints Timothy Henrichs as Chief Financial Officer

    CARMEL, Ind., Jan. 31, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the appointment of Timothy Henrichs as Chief Financial Officer (CFO), effective February 5, 2024. As part of his appointment, Mr. Henrichs has resigned as an independent director on the board of NeurAxis (the "Board"). "We are thrilled to announce Tim as the new Chief Financial Officer of NeurAxis," said Brian Carrico, President and Chief Executive Officer of NeurAxis. "His extensive experience will be highly valuable

    1/31/24 9:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Financials

    Live finance-specific insights

    View All

    NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

    CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter 2025 for the period ended June 30, 2025. 2Q25 Financial highlights Revenues increased 46% year over year to $894 thousand in 2Q25 compared to $612 thousand in 2Q24.Operating expenses decreased 10% year over year in 2Q25 compared to 2Q24.Operating loss improved by 22% compared to the second quarter of 2024.Cash balance was $6 million as of June 30, 2025. The Company secured $5 million through an equity-on

    8/12/25 7:00:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

    CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its second quarter 2025, for the period ended June 30, 2025, on Tuesday, August 12, 2025, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 12, 2025, at 9:00 am ET to review the results. Conference Call Details Date and Time: Tuesday, August 12, 2024, at 9:00am ET Live Webcast Information: Interested parties can access the conference call via a live webcast, whi

    8/5/25 8:30:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues

    CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.Cash balance was $2.0 million as

    5/12/25 8:15:00 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $NRXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuraxis Inc.

    SC 13D - Neuraxis, INC (0001933567) (Subject)

    12/2/24 11:53:07 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Neuraxis Inc.

    SC 13G - Neuraxis, INC (0001933567) (Subject)

    12/2/24 9:57:28 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuraxis Inc.

    SC 13G/A - Neuraxis, INC (0001933567) (Subject)

    10/8/24 7:30:11 AM ET
    $NRXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care